摘要
目的探讨肝移植受者他克莫司治疗窗浓度参考范围。方法采用化学发光微粒子免疫法(CMIA)监测他克莫司全血谷浓度(C0),结合受者的临床表现及生化指标,对74例肝移植受者的305例次监测结果进行分析。结果肝移植术后前3个月他克莫司C0为(7.0±3.6)ng/ml,3个月后为(5.5±2.3)ng/ml。术后发生急性排斥反应4例次,肝、肾毒性54例次。结论建议将实验室他克莫司治疗窗范围进行调整:肝移植术后前3个月为7～15ng/ml,3个月后为5～10ng/ml,以保证免疫抑制效果,减少排斥反应和肝、肾毒性。
Objective To investigate the therapeutic window concentration of Tacrolimus in liver transplant recipi- ents. Methods 305 whole blood trough concentration of Tacrolimus in 74 liver transplant recipients were determined by chemiluminescent microparticle immunoassay （CMIA） combined with the clinial presentations and biochemical indexes of re- cipients. Results The whole blood trough concentration of tacrolimus was （7.0 -＋ 3.6） ng/ml within the first 3 months,and it was （5.5 ＋ 2.3 ） ng/ml 3 months after transplantation. There were 4 case-times of acute rejection and 54 case-times of liver and kidney toxicity. Conclusion The blood trough level of Tacrolimus should be adjusted as follows ：7 - 15 ng/ml within the first 3 months ,5 ~ 10ng/ml from the third month after transplantation. This range of therapeutic window concentration was ideal for liver transplant recipients with less acute rejection and toxicity effects.
出处
《临床合理用药杂志》
2012年第26期15-16,共2页
Chinese Journal of Clinical Rational Drug Use
